US-based therapeutic developer for muscular dystrophy PTC Therapeutics establishes corporation in Tokyo

Mar 27, 2017

PTC Therapeutics Inc.PTC Therapeutics Inc.External site: a new window will open., a US company engaged in development, manufacturing and sales of a drug for muscular dystrophy (MD), established PTC Therapeutics Japan in August, 2015. Muscular dystrophy is a genetic disorder that causes necrosis of skeletal muscles. Designating it a difficult-to-treat disease, the Japanese government provides support for the development of therapeutic drugs for the disease. PTC Therapeutics's drug for MD has obtained marketing certification in Europe and it is already in the process of marketing certification procedures in Japan.

For the establishment of PTC Therapeutics' subsidiary in Japan, the JETRO Invest Japan Business Support Center (IBSC) provided information on approval and the certification system related to pharmaceuticals in Japan.

Contact Us

Investing in Japan

We will do our very best to support your business expansion into and within Japan. Please feel free to contact us via the form below for any inquiries.

Inquiry Form

JETRO Worldwide

Our network covers over 50 countries worldwide. You can contact us at one of our local offices near you for consultation.

Overseas Offices